Skip to content
10-Q

Quarterly Report

Design Therapeutics, Inc. DSGN

0000950170-25-065643

← back to feed
Filed
May 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 56.77M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $13.67M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $22.56M
Current Liabilities Q1 2025 · Mar 31, 2025 $8.24M
Current Liabilities Q1 2025 · Dec 31, 2024 $8.46M
Total Liabilities Q1 2025 · Mar 31, 2025 $9.56M
Total Liabilities Q1 2025 · Dec 31, 2024 $10M
Current Assets Q1 2025 · Mar 31, 2025 $233.64M
Current Assets Q1 2025 · Dec 31, 2024 $248.04M
Total Assets Q1 2025 · Mar 31, 2025 $237.48M
Total Assets Q1 2025 · Dec 31, 2024 $252.09M
Shares Diluted Q1 2025 · Mar 31, 2024 56.49M sh
Capex Q1 2025 · Mar 31, 2024 $195K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$12.44M
Stockholders Equity Q1 2025 · Mar 31, 2024 $269.56M
Stockholders Equity Q1 2025 · Dec 31, 2023 $277.69M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.20
Eps Basic Q1 2025 · Mar 31, 2024 −$0.20
Sga Expense Q1 2025 · Mar 31, 2024 $4.6M
Rd Expense Q1 2025 · Mar 31, 2024 $9.8M
Net Income Q1 2025 · Mar 31, 2024 −$11.11M
Operating Income Q1 2025 · Mar 31, 2024 −$14.4M